Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
GenVec Announces New Research at AACR on Selectivity and Mechanism of Action of TNF-Based Anti-Cancer Therapy
May 1st, 2007
GenVec, Inc. (Nasdaq:GNVC) announced data from two studies presented at the 97th annual meeting of the American Association of Cancer Research (AACR) that further support the use of adenovector systems to deliver the gene for tumor necrosis factor-alpha (TNF(alpha)). GenVec's lead product candidate, TNFerade(TM) biologic (TNFerade) is an adenovector, or DNA carrier, which contains the gene for TNF(alpha), a potent immune system protein with well-documented anti-cancer effects. TNFerade is currently in a pivotal Phase II/III trial for locally advanced pancreatic cancer. GenVec researchers presented a poster entitled, "Selective delivery of tumor necrosis factor to...
Source: Cancer Weekly (2007-05-01)
|
